Trials / Recruiting
RecruitingNCT07355062
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Veverimer in Adults With CKD and Metabolic Acidosis (The REVIVE Study)
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Renibus Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Veverimer | Group 1: 9 g veverimer BID |
| DRUG | Placebo | Group 2: 9 g PBO BID |
Timeline
- Start date
- 2026-01-13
- Primary completion
- 2027-06-01
- Completion
- 2027-06-01
- First posted
- 2026-01-21
- Last updated
- 2026-04-02
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07355062. Inclusion in this directory is not an endorsement.